The University of Chicago Header Logo

Connection

Ravi Salgia to Proto-Oncogene Proteins p21(ras)

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Proto-Oncogene Proteins p21(ras).
Ravi Salgia
Connection Strength
4.699
Proto-Oncogene Proteins p21(ras)
  1. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023 01; 9(1):42-54.
    View in: PubMed
    Score: 0.821
  2. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
    View in: PubMed
    Score: 0.752
  3. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.739
  4. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
    View in: PubMed
    Score: 0.726
  5. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12.
    View in: PubMed
    Score: 0.527
  6. A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11).
    View in: PubMed
    Score: 0.220
  7. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
    View in: PubMed
    Score: 0.219
  8. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
    View in: PubMed
    Score: 0.171
  9. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.148
  10. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9.
    View in: PubMed
    Score: 0.128
  11. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24.
    View in: PubMed
    Score: 0.089
  12. Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240.
    View in: PubMed
    Score: 0.052
  13. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8.
    View in: PubMed
    Score: 0.031
  14. Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. PLoS One. 2014; 9(3):e90059.
    View in: PubMed
    Score: 0.028
  15. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.025
  16. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.